Helixmith Co.

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Helixmith Co. sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed top decile by trial count

Helixmith Co.: 12 sponsored US clinical trials, none currently recruiting.

Helixmith Co. sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 5 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Neuropathy, Painful, with 1 trials.

Top-decile sponsor footprint

Helixmith Co. ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 2

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

NCT05176093
COMPLETED Phase 3

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

NCT04873232
COMPLETED Phase 2

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

NCT04632225
COMPLETED Phase 3

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

NCT04469270
COMPLETED Phase 3

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
TERMINATED Phase 3

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCT02563522
COMPLETED Phase 3

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT02427464
COMPLETED Phase 1

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

NCT02039401
COMPLETED Phase 2

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
COMPLETED Phase 2

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

NCT01064440
COMPLETED Phase 1

Gene Therapy for Painful Diabetic Neuropathy

NCT01002235
COMPLETED Phase 1

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

NCT00696124

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4
Phase 3 5

Therapeutic Areas

Diabetic Neuropathy, Painful 1
Critical Limb Ischemia 1
Amyotrophic Lateral Sclerosis 1

How the Helixmith Co. archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 5 late (III/IV) vs 7 early (I/II) (balanced across stages).

Top condition: Diabetic Neuropathy, Painful (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Helixmith Co.: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Helixmith Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Helixmith Co.Alachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Helixmith Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Helixmith Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Helixmith Co. page

12 registered trials is a research-attention snapshot, not an endorsement of Helixmith Co. or any single study.

  • None of Helixmith Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Diabetic Neuropathy, Painful is the condition Helixmith Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Neuropathy, Painful trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Helixmith Co. pipeline card: 12 registered trials from official public datasets.Report a data error.